Catalent reports 13% revenue jump in Q4; Central Europe CRO market to grow 7% a year;

> Catalent's fourth-quarter revenue spiked 13% to $478 million, thanks largely to its February acquisition of Aptuit. Report

> CROs in Central Europe have been fighting for market share of late, and a new report says the clinical trial market there will grow by about 7% per year through 2014. More

> China's WuXi PharmaTech has signed a deal to manufacture the HIV drug ibalizumab for TaiMed Biologics. News

> The Regulatory Affairs Professionals Society says CROs in emerging markets can benefit from taking the organization's test, bringing them up to speed on regulatory requirements around the world. Article

> CMC Biologics has appointed a new general manager for its Denmark CMO facility, tapping Patricio Massera to head the plant. Story

> The progress of personalized medicine suggest that whether or not a treatment is effective is based on a complex network of varying genes, flying in the face of the FDA's methods of isolating variables in clinical trials. What does that mean for the future of drug research? Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.